AbCellera Biologics Inc.
AbCellera Biologics Inc. (ABCL): 12 pipeline candidates · 2 upcoming catalysts · ~24 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
24.2 months
D/E 0.39 · 0% dilution
Lead: Phase 1/Phase 2
12 candidates
2 upcoming, next in ~4663d
4 buys · 0 sells (180d)
A transparent, data-derived signal for AbCellera Biologics Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.7B
Cash
$102.1M
Quarterly Burn
$33.5M
Runway
24.2 mo
Revenue
$8.3M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (12 candidates)
| Drug | Phase |
|---|---|
| 5-FU | Phase 1 |
| ABCL386 | Phase 1/Phase 2 |
| ABCL575 | Phase 1 |
| ABCL635 | Phase 1/Phase 2 |
| ABCL688 | Phase 1/Phase 2 |
| Cetuximab | Phase 1 |
| Etoposide | Phase 1 |
| HCB101 | Phase 1 |
| Leucovorin | Phase 1 |
| Pertuzumab | Phase 1 |
Showing 10 of 12 candidates. Sign up for full pipeline.
Upcoming Catalysts (2)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
133
Total value held
$311.4M
| Holder | Shares | Value |
|---|---|---|
| baker bros. advisors lp | 30,275,938 | $105.7M |
| two sigma investments, lp | 10,562,065 | $36.9M |
| jefferies financial group inc. | 5,482,400 | $19.1M |
| blackrock, inc. | 4,040,236 | $14.1M |
| driehaus capital management llc | 4,024,779 | $14.0M |
| goldman sachs group inc | 3,751,212 | $13.1M |
| bank of america corp /de/ | 2,999,936 | $10.5M |
| alyeska investment group, l.p. | 2,592,105 | $9.0M |
| tudor investment corp et al | 2,273,489 | $7.9M |
| morgan stanley | 2,224,829 | $7.8M |
Showing top 10 of 133 institutional holders of AbCellera Biologics Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in AbCellera Biologics Inc.'s pipeline?
AbCellera Biologics Inc. (ABCL) has 12 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is AbCellera Biologics Inc.'s lead drug candidate?
AbCellera Biologics Inc.'s most advanced tracked candidate is 5-FU (Phase 1) for Solid Cancer.
What is AbCellera Biologics Inc.'s next catalyst?
AbCellera Biologics Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: KHAPZORY" — expected March 25, 2039.
What is AbCellera Biologics Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, AbCellera Biologics Inc. has approximately 24.2 months of cash runway.
What is AbCellera Biologics Inc.'s market capitalization?
AbCellera Biologics Inc.'s market capitalization is approximately $1.7B.
Get the full picture on AbCellera Biologics Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.